Patients characteristics of trials included in the meta-analysis
| Study (reference)* | Accrual period (y) | Patients randomised (n) | Male >(%) | Mean age (y) | Histology (%) | Preoperative stage (% of patients) | |||
|---|---|---|---|---|---|---|---|---|---|
| SCC | ADENO | ||||||||
| *For expansion of the study names, see corresponding reference. | |||||||||
| CRT+S, chemoradiotherapy plus surgery; S, surgery; SCC, squamous cell carcinoma; ADENO, adenocarcinoma; NR, not reported. | |||||||||
| 1 | Nygaard et al12 | 1983–88 | CRT+S | 53 | 70 | 60.1 | 100 | 0 | I–II (100) |
| S | 50 | 75 | 61.4 | 100 | 0 | I–II (100) | |||
| 2 | Le Prise et al13 | 1988–91 | CRT+S | 41 | 93 | 56 | 100 | 0 | I (12.2); II (65.8); not specified (22) |
| S | 45 | 93 | 59 | 100 | 0 | I (35.5); II (55.6); not specified (8.9) | |||
| 3 | Apinop et al14 | 1986–92 | CRT+S | 35 | 80 | 59.6 | 100 | 0 | IIb (17.1); III (82.9) |
| S | 34 | 76 | 59.8 | 100 | 0 | IIb (14.8); III (82.3); not specified (5.9) | |||
| 4 | Walsh et al15 | 1990–95 | CRT+S | 58 | 67 | 65 | 0 | 100 | NR |
| S | 55 | 80 | 65 | 0 | 100 | NR | |||
| 5 | Bosset et al16 | 1989–95 | CRT+S | 151 | 90 | 57 | 100 | 0 | I (15.9); IIa (56.9); IIb (21.8) not specified (8) |
| S | 146 | 96 | 57 | 100 | 0 | I (17.1); IIa (56.2); IIb (21.9) not specified (4.8) | |||
| 6 | Urba et al17 | 1989–94 | CRT+S | 50 | 84 | 62 | 26 | 74 | I–IIa (60); IIb–III (40) |
| S | 50 | 86 | 64 | 24 | 76 | I–IIa (56); IIb–III (44) | |||